Monoclonal antibodies for prophylactic and therapeutic use against viral infections

Vaccine

Volumn 31, Issue 12, 2013, Pages 1553-1559

  Both, Leonard ^a,b   Banyard, Ashley C ^b   Van Dolleweerd, Craig ^a   Wright, Edward ^c   Ma, Julian K C ^a   Fooks, Anthony R ^b,d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

^c UNIVERSITY OF WESTMINSTER   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antibody engineering; Antiviral immunity; Monoclonal antibody; Serum therapy

Indexed keywords

CL 184; CYANOVIRIN; EPITOPE; GLYCOPROTEIN B; GLYCOPROTEIN GP 160; HEPATITIS B ANTIBODY; HERPES ZOSTER IMMUNOGLOBULIN; HUMAN IMMUNODEFICIENCY VIRUS MONOCLONAL ANTIBODY B12; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G NEW ANTIGEN RECEPTOR ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN NEW ANTIGEN RECEPTORS; MEDI 557; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB; RABIES IMMUNOGLOBULIN; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; ANTIBODY TITER; ANTIGEN BINDING; BINDING AFFINITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; EBOLA VIRUS; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFLUENZA VIRUS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; RABIES VIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SARS CORONAVIRUS; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIVIRAL AGENTS; HUMANS; IMMUNIZATION, PASSIVE; PROTEIN ENGINEERING; VIRUS DISEASES;

EID: 84875237748     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.025     Document Type: Review

References (100)

1. Both L., Banyard A.C., van Dolleweerd C., Horton D.L., Ma J.K., Fooks A.R. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012, 12(5):397-407.
2. Casadevall A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2(9):695-703.
3. von Behring E., Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals, 1890 (reprint). Mol Immunol 1991, 28(12):1317-1320.
4. Marasco W.A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007, 25(12):1421-1434.
5. An immunising serum against Rinderpest. Br Med J 1897, 2(1925):1517.
6. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006, 193(6):796-801.
7. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity, 1975 (reprint). J Immunol 2005, 174(5):2453-2455.
8. Hoogenboom H.R. Overview of antibody phage-display technology and its applications. Methods Mol Biol 2002, 178:1-37.
9. ter Meulen J., Bakker A.B., van den Brink E.N., Weverling G.J., Martina B.E., Haagmans B.L., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363(9427):2139-2141.
10. Bossart K.N., Geisbert T.W., Feldmann H., Zhu Z., Feldmann F., Geisbert J.B., et al. A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci Transl Med 2011, 3(105):105ra103.
11. Boivin G., Caouette G., Frenette L., Carbonneau J., Ouakki M., De Serres G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol 2008, 42:52-57.
12. Gill M.A., Welliver R.C. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin Biol Ther 2009, 9(10):1335-1345.
13. Wu H., Pfarr D.S., Losonsky G.A., Kiener P.A. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008, 317:103-123.
14. Saylor C., Dadachova E., Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27(6):38-46.
15. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010, 10(5):301-316.
16. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 2006, 6(5):343-357.
17. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7(9):715-725.
18. Pantophlet R. Antibody epitope exposure and neutralization of HIV-1. Curr Pharm Des 2010, 16(33):3729-3743.
19. Olson W.C., Jacobson J.M. CCR5 monoclonal antibodies for HIV-1 therapy. Curr Opin HIV AIDS 2009, 4(2):104-111.
20. Imai M., Sugimoto K., Okazaki K., Kida H. Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res 1998, 53(2):129-139.
21. Hultberg A., Temperton N.J., Rosseels V., Koenders M., Gonzalez-Pajuelo M., Schepens B., et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 2011, 6(4):e17665.
22. Krawczyk A., Krauss J., Eis-Hübinger A.M., Däumer M.P., Schwarzenbacher R., Dittmer U., et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol 2011, 85(4):1793-1803.
23. Webster R.G., Laver W.G. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J Immunol 1967, 99(1):49-55.
24. Law M., Hangartner L. Antibodies against viruses: passive and active immunization. Curr Opin Immunol 2008, 20(4):486-492.
25. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002, 83(Pt 9):2091-2108.
26. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 1988, 62(7):2321-2328.
27. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4(5):388-393.
28. Willey S., Aasa-Chapman M.M. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008, 16(12):596-604.
29. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449(7158):101-104.
30. Warrell M.J. The challenge to provide affordable rabies post-exposure treatment. Vaccine 2003, 21(7-8):706-709.
31. Nasser R., Pelegrin M., Michaud H.A., Plays M., Piechaczyk M., Gros L. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010, 84(19):10169-10181.
32. Michaud H.A., Gomard T., Gros L., Thiolon K., Nasser R., Jacquet C., et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010, 6(6):e1000948.
33. Gal-Tanamy M., Keck Z.Y., Yi M., McKeating J.A., Patel A.H., Foung S.K., et al. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A 2008, 105(49):19450-19455.
34. Lee C.Y., Kam Y.W., Fric J., Malleret B., Koh E.G., Prakash C., et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog 2011, 7(12):e1002390.
35. Prabakaran M., Prabhu N., He F., Hongliang Q., Ho H.T., Qiang J., et al. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 2009, 4(5):e5672.
36. Zhu Q., McAuliffe J.M., Patel N.K., Palmer-Hill F.J., Yang C.F., Liang B., et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis 2011, 203(5):674-682.
37. Rockx B., Donaldson E., Frieman M., Sheahan T., Corti D., Lanzavecchia A., et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 2010, 201(6):946-955.
38. Müller T., Dietzschold B., Ertl H., Fooks A.R., Freuling C., Fehlner-Gardiner C., et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009, 3(11):e542.
39. Armbruster C., Stiegler G.M., Vcelar B.A., Jäger W., Köller U., Jilch R., et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004, 54(5):915-920.
40. Prosniak M., Faber M., Hanlon C.A., Rupprecht C.E., Hooper D.C., Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 2003, 188(1):53-56.
41. Sawada H., Iwasa S., Nishimura O., Kitano K. Efficient production of anti-hepatitis B virus antibodies and their neutralizing activity in chimpanzees. Appl Microbiol Biotechnol 1995, 43(3):445-451.
42. Marzi A., Yoshida R., Miyamoto H., Ishijima M., Suzuki Y., Higuchi M., et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012, 7(4):e36192.
43. Qiu X., Audet J., Wong G., Pillet S., Bello A., Cabral T., et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012, 4(138):138ra81.
44. Rupprecht C.E., Hanlon C.A., Hemachudha T. Rabies re-examined. Lancet Infect Dis 2002, 2(6):327-343.
45. Banyard A.C., Hayman D., Johnson N., McElhinney L., Fooks A.R. Bats and lyssaviruses. Adv Virus Res 2011, 79:239-289.
46. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine 2010, 28(23):3896-3901.
47. Sloan S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007, 25(15):2800-2810.
48. Kramer R.A., Marissen W.E., Goudsmit J., Visser T.J., Clijsters-Van der Horst M., Bakker A.Q., et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 2005, 35(7):2131-2145.
49. Bakker A.B., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005, 79(14):9062-9068.
50. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 2005, 79(8):4672-4678.
51. de Kruif J., Bakker A.B., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007, 58:359-368.
52. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26(47):5922-5927.
53. Ter Meulen J., van den Brink E.N., Poon L.L., Marissen W.E., Leung C.S., Cox F., et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006, 3(7):e237.
54. Zwick M.B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D.R., et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001, 75(24):12198-12208.
55. Laal S., Burda S., Gorny M.K., Karwowska S., Buchbinder A., Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 1994, 68(6):4001-4008.
56. Li A., Katinger H., Posner M.R., Cavacini L., Zolla-Pazner S., Gorny M.K., et al. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 1998, 72(4):3235-3240.
57. Drew P.D., Moss M.T., Pasieka T.J., Grose C., Harris W.J., Porter A.J. Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not. J Gen Virol 2001, 82(8):1959-1963.
58. Klein J.S., Gnanapragasam P.N., Galimidi R.P., Foglesong C.P., West A.P., Bjorkman P.J. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 2009, 106(18):7385-7390.
59. Berdoz J., Blanc C.T., Reinhardt M., Kraehenbuhl J.P., Corthésy B. In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci U S A 1999, 96(6):3029-3034.
60. Ma J.K., Hiatt A., Hein M., Vine N.D., Wang F., Stabila P., et al. Generation and assembly of secretory antibodies in plants. Science 1995, 268(5211):716-719.
61. Wu H., Pfarr D.S., Tang Y., An L.L., Patel N.K., Watkins J.D., et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005, 350(1):126-144.
62. Edwards M.J., Dimmock N.J. Hemagglutinin1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol 2001, 75(21):10208-10218.
63. Klein J.S., Bjorkman P.J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010, 6(5):e1000908.
64. Zhu P., Liu J., Bess J., Chertova E., Lifson J.D., Grisé H., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441(7095):847-852.
65. West A.P., Galimidi R.P., Foglesong C.P., Gnanapragasam P.N., Huey-Tubman K.E., Klein J.S., et al. Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol 2009, 83(1):98-104.
66. Klein J.S., Webster A., Gnanapragasam P.N., Galimidi R.P., Bjorkman P.J. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS 2010, 24(11):1633-1640.
67. Luo X.M., Lei M.Y., Feidi R.A., West A.P., Balazs A.B., Bjorkman P.J., et al. Dimeric 2G12 as a potent protection against HIV-1. PLoS Pathog 2010, 6(12):e1001225.
68. Wolbank S., Kunert R., Stiegler G., Katinger H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 2003, 77(7):4095-4103.
69. Mouquet H., Warncke M., Scheid J.F., Seaman M.S., Nussenzweig M.C. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A 2012, 109(3):875-880.
70. Schanzer J., Jekle A., Nezu J., Lochner A., Croasdale R., Dioszegi M., et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011, 55(5):2369-2378.
71. Sexton A., Harman S., Shattock R.J., Design Ma J.K. expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 2009, 23(10):3590-3600.
72. Jekle A., Chow E., Kopetzki E., Ji C., Yan M.J., Nguyen R., et al. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Res 2009, 83(3):257-266.
73. Ji C., Kopetzki E., Jekle A., Stubenrauch K.G., Liu X., Zhang J., et al. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J Biol Chem 2009, 284(8):5175-5185.
74. Kopetzki E., Jekle A., Ji C., Rao E., Zhang J., Fischer S., et al. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virol J 2008, 1(5):56.
75. Barnett B.B., Smee D.F., Malek S.M., Sidwell R.W. Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells. Antimicrob Agents Chemother 1996, 40(2):470-472.
76. Zhao X.L., Chen W.Q., Yang Z.H., Li J.M., Zhang S.J., Tian L.F. Selection and affinity maturation of human antibodies against rabies virus from a scFv gene library using ribosome display. J Biotechnol 2009, 144(4):253-258.
77. Duan Y., Gu T.J., Jiang C.L., Yuan R.S., Zhang H.F., Hou H.J., et al. A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency. Mol Immunol 2012, 51(2):188-196.
78. Ray K., Embleton M.J., Jailkhani B.L., Bhan M.K., Kumar R. Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1. Clin Exp Immunol 2001, 125(1):94-101.
79. Houimel M., Dellagi K. Isolation and characterization of human neutralizing antibodies to rabies virus derived from a recombinant immune antibody library. J Virol Methods 2009, 161(2):205-215.
80. Liu X., Lin H., Tang Q., Li C., Yang S., Wang Z., et al. Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine. PLoS One 2011, 6(5):e19848.
81. Forsman A., Beirnaert E., Aasa-Chapman M.M., Hoorelbeke B., Hijazi K., Koh W., et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008, 82(24):12069-12081.
82. Walsh R., Nuttall S., Revill P., Colledge D., Cabuang L., Soppe S., et al. Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology 2011, 411(1):132-141.
83. Goodchild S.A., Dooley H., Schoepp R.J., Flajnik M., Lonsdale S.G. Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries. Mol Immunol 2011, 48(15-16):2027-2037.
84. Shadman K.A., Wald E.R. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011, 11(11):1455-1467.
85. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010, 10(5):345-352.
86. Moldt B., Schultz N., Dunlop D.C., Alpert M.D., Harvey J.D., Evans D.T., et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. J Virol 2011, 85(20):10572-10581.
87. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
88. Klasse P.J., Burton D.R. Antibodies to West Nile virus: a double-edged sword. Cell Host Microbe 2007, 1(2):87-89.
89. Halstead S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979, 140(4):527-533.
90. Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010, 6(2):e1000790.
91. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 2001, 293(5532):1155-1159.
92. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schülke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001, 75(22):10906-10911.
93. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(5924):246-251.
94. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16(3):265-273.
95. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333(6044):843-850.
96. Morrey J.D., Siddharthan V., Wang H., Hall J.O., Skirpstunas R.T., Olsen A.L., et al. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol 2008, 14(2):152-163.
97. Roy A., Hooper D.C. Immune evasion by rabies viruses through the maintenance of blood-brain barrier integrity. J Neurovirol 2008, 14(5):401-411.
98. Pardridge W.M. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002, 1(2):131-139.
99. Marshall L., Kelsall W., Gooding N. A cost-effective approach to administering palivizumab in a centralised nurse-led community clinic. Arch Dis Child 2008, 93(7):638.
100. Fox J.L. HIV drugs made in tobacco. Nat Biotechnol 2011, 29(10):852.